Cliff Asness's ABBV Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 926.8K shares of AbbVie Inc. (ABBV) worth $209.65 M, representing 0.13% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in ABBV, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2017, adding 2.8M shares. Largest reduction occurred in Q2 2015, reducing 3.3M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's AbbVie (ABBV) Holding Value Over Time
Track share changes against reported price movement
Quarterly AbbVie (ABBV) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2013 | +309,147 | New Buy | 309,147 | $44.73 |
| Q4 2013 | +703,435 | Add 227.54% | 1.01 M | $52.81 |
| Q1 2014 | +1.95 M | Add 192.90% | 2.97 M | $51.40 |
| Q2 2014 | +314,100 | Add 10.59% | 3.28 M | $56.44 |
| Q3 2014 | -773,075 | Reduce 23.57% | 2.51 M | $57.76 |
| Q4 2014 | +1.5 M | Add 59.88% | 4.01 M | $65.44 |
| Q1 2015 | +2.72 M | Add 67.83% | 6.73 M | $58.54 |
| Q2 2015 | -3.26 M | Reduce 48.45% | 3.47 M | $67.19 |
| Q3 2015 | -2.24 M | Reduce 64.64% | 1.23 M | $54.41 |
| Q4 2015 | +125,319 | Add 10.22% | 1.35 M | $59.24 |
| Q1 2016 | -283,076 | Reduce 20.95% | 1.07 M | $57.12 |
| Q2 2016 | -544,432 | Reduce 50.96% | 523,964 | $61.91 |
| Q3 2016 | +132,726 | Add 25.33% | 656,690 | $63.07 |
| Q4 2016 | -63,576 | Reduce 9.68% | 593,114 | $62.62 |
| Q1 2017 | +347,710 | Add 58.62% | 940,824 | $65.16 |
| Q2 2017 | -46,033 | Reduce 4.89% | 894,791 | $72.51 |
| Q3 2017 | +2.85 M | Add 318.01% | 3.74 M | $88.86 |
| Q4 2017 | +752,859 | Add 20.13% | 4.49 M | $96.71 |
| Q1 2018 | +507,695 | Add 11.30% | 5 M | $94.65 |
| Q2 2018 | -938,798 | Reduce 18.77% | 4.06 M | $93.50 |
| Q3 2018 | +931,390 | Add 22.93% | 4.99 M | $94.58 |
| Q4 2018 | -967,494 | Reduce 19.38% | 4.03 M | $92.19 |
| Q1 2019 | +950,737 | Add 23.62% | 4.98 M | $80.42 |
| Q2 2019 | -2.04 M | Reduce 40.98% | 2.94 M | $72.03 |
| Q3 2019 | -1.79 M | Reduce 60.91% | 1.15 M | $75.32 |
| Q4 2019 | +623,364 | Add 54.29% | 1.77 M | $88.41 |
| Q1 2020 | +1.26 M | Add 70.99% | 3.03 M | $76.16 |
| Q2 2020 | +2.3 M | Add 75.82% | 5.33 M | $96.16 |
| Q3 2020 | -1.65 M | Reduce 31.05% | 3.67 M | $86.90 |
| Q4 2020 | -1.21 M | Reduce 32.96% | 2.46 M | $105.63 |
| Q1 2021 | -205,311 | Reduce 8.34% | 2.26 M | $107.71 |
| Q2 2021 | -387,539 | Reduce 17.18% | 1.87 M | $111.88 |
| Q3 2021 | +103,628 | Add 5.55% | 1.97 M | $107.87 |
| Q4 2021 | +57,832 | Add 2.93% | 2.03 M | $135.40 |
| Q1 2022 | -232,348 | Reduce 11.44% | 1.8 M | $162.11 |
| Q2 2022 | -131,592 | Reduce 7.32% | 1.67 M | $151.90 |
| Q3 2022 | -208,400 | Reduce 12.51% | 1.46 M | $134.21 |
| Q4 2022 | -36,141 | Reduce 2.48% | 1.42 M | $161.03 |
| Q1 2023 | -227,583 | Reduce 16.01% | 1.19 M | $158.06 |
| Q2 2023 | -28,800 | Reduce 2.41% | 1.17 M | $133.05 |
| Q3 2023 | +331,662 | Add 28.46% | 1.5 M | $149.06 |
| Q4 2023 | +348,011 | Add 23.25% | 1.85 M | $154.78 |
| Q1 2024 | -306,614 | Reduce 16.62% | 1.54 M | $181.01 |
| Q2 2024 | -134,055 | Reduce 8.71% | 1.4 M | $169.33 |
| Q3 2024 | +307,306 | Add 21.88% | 1.71 M | $194.69 |
| Q4 2024 | -263,367 | Reduce 15.39% | 1.45 M | $176.91 |
| Q1 2025 | -674,261 | Reduce 46.55% | 774,106 | $205.97 |
| Q2 2025 | -176,114 | Reduce 22.75% | 597,992 | $183.49 |
| Q3 2025 | +328,850 | Add 54.99% | 926,842 | $226.20 |
Cliff Asness's AbbVie Investment FAQs
Cliff Asness first purchased AbbVie Inc. (ABBV) in Q3 2013, acquiring 309,147 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held AbbVie Inc. (ABBV) for 49 quarters since Q3 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to AbbVie Inc. (ABBV) was in Q3 2017, adding 3,740,301 shares worth $332.36 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 926,842 shares of AbbVie Inc. (ABBV), valued at approximately $209.65 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, AbbVie Inc. (ABBV) represents approximately 0.13% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in AbbVie Inc. (ABBV) was 6,726,677 shares, as reported at the end of Q1 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.